Accordingly, targeting GCS by epigenetic or pharmacological approaches reduced the glucosylceramide and ganglioside content of MEB4 mouse melanoma cells without affecting cell proliferation and viability in vitro but greatly impaired the tumor progression in immunocompetent mice (48). The gene discussed is UGCG; the disease is neoplasm.